Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).

Erenie H Guirguis John A Dougherty Krisy-Ann ThornbyYasmin GraceKeri Mack

Published in: The Annals of pharmacotherapy (2024)

Resmetirom serves as an attractive option in patients diagnosed with NASH with evidence of advanced fibrosis (F2-F3) in combination with exercise, diet, and other multimodal therapies targeting metabolic risk factors.

Keyphrases

drug administration
risk factors
end stage renal disease
physical activity
newly diagnosed
high intensity
peritoneal dialysis
patient reported outcomes
pain management
chronic pain
resistance training
body composition
adverse drug
drug induced